Anchor Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Anchor Therapeutics - overview
Established
2006
Location
Cambridge, MA, US
Primary Industry
Pharmaceuticals
About
Anchor Therapeutics specializes in the sale of premium domain names, catering to businesses and entrepreneurs aiming for a distinctive online presence. Their offerings ensure a secure purchasing process backed by a satisfaction guarantee. Anchor Therapeutics, founded in 2006 and headquartered in Cambridge, US, focuses on providing high-value domain names. The company has completed a total of 3 deals, with its most recent funding round occurring on August 20, 2010.
During this Series B round, Anchor Therapeutics raised USD 10. 00 mn from investors including HealthCare Ventures, Novartis Venture Fund, and TVM Capital Life Science. The current company valuation stands at USD 32. 06 mn.
Anchor Therapeutics offers premium domain names for sale, including the notable AnchorTX. com, which is listed at a price of USD 7,695. Clients can choose to purchase outright or opt for a payment plan of USD 320. 63 per month over 24 months.
The company provides secure transactions through payment methods like PayPal and Escrow. com, targeting a diverse customer base across technology, finance, and e-commerce sectors primarily in North America and Europe. Anchor Therapeutics generates revenue through the direct sale of domain names, allowing clients flexible purchasing options. The domain name AnchorTX.
com is available for USD 7,695 or a payment plan of USD 320. 63 monthly for 24 months. This dual approach caters to various buyers, from startups to established enterprises, through secure transaction methods. Anchor Therapeutics plans to leverage its recent Series B funding of USD 10.
00 mn to enhance its product offerings and expand its market presence. This includes upcoming initiatives aimed at enhancing their domain acquisition process and targeting additional regions in North America and Europe. The funding is expected to support these strategic expansions and product developments as they look to broaden their client base and improve their services.
Current Investors
HealthCare Ventures, TVM Capital Life Science, Novartis Venture Fund
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.anchortx.com
Company Stage
Series B
Total Amount Raised
Subscriber access only

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.